$0.34
(Market cap
$2,201 Mln
Revenue (TTM)
$453 Mln
P/E Ratio
--
P/B Ratio
3.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
112,354,858
9 Years Aggregate
CFO
$-1,695.65 Mln
EBITDA
$-2,151.45 Mln
Net Profit
$-2,235.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zai Lab - ADR
| 17.2 | -5.9 | 3.2 | -26.5 | -14.9 | -33.0 | -- |
|
BSE Sensex
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Zai Lab - ADR
| -32.6 | -4.1 | -11.0 | -51.2 | -53.6 | 225.4 | 79.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zai Lab - ADR
|
20.7 | 2,201.0 | 453.3 | -178.1 | -27.8 | -25.1 | -- | 3.2 |
| 813.3 | 50,825.9 | 5,779.3 | 1,830.5 | 8.7 | 27.3 | 36.1 | 6.6 | |
| 19.5 | 1,205.0 | 0.0 | -167.9 | -- | -128.7 | -- | 5.6 | |
| 106.9 | 10,398.1 | 6,066.4 | 609.2 | 18.3 | 16.7 | 17.9 | 4.2 | |
| 21.7 | 11,687.9 | 19,358.7 | 944.6 | 9.0 | 5.5 | 11.3 | 0.8 | |
| 27.5 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 0.3 | 12.2 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 | |
| 13.0 | 891.5 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.4 | 3.4 | |
| 3.0 | 585.2 | 3.2 | -198.4 | -4,800.7 | -166.3 | -- | 7.6 | |
| 6.5 | 338.7 | 0.8 | -75.0 | -6,681.4 | -- | -- | 6.7 |
Shareholding Pattern
View DetailsAbout Zai Lab - ADR
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products... include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China. Address: Building B, Pudong, China, 201203 Read more
-
Founder, Chairperson & CEO
Dr. Ying Du Ph.D.
-
Founder, Chairperson & CEO
Dr. Ying Du Ph.D.
-
Headquarters
Pudong
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Zai Lab - ADR
What is the current share price of Zai Lab Limited - ADR Today?
The share price of Zai Lab Limited - ADR is $20.67 (NASDAQ) as of 15-May-2026 10:41 EDT. Zai Lab Limited - ADR has given a return of -14.93% in the last 3 years.
What is the current PB & PE ratio of Zai Lab Limited - ADR?
Since, TTM earnings of Zai Lab Limited - ADR is negative, P/E ratio is not available.
The P/B ratio of Zai Lab Limited - ADR is 3.15 times as on 12-May-2026, a 39 discount to its peers’ median range of 5.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-11.11
|
2.73
|
|
2024
|
-10.37
|
3.17
|
|
2023
|
-79.26
|
33.31
|
|
2022
|
-66.48
|
28.19
|
|
2021
|
-85.15
|
43.47
|
What is the 52 Week High and Low of Zai Lab Limited - ADR?
The 52-week high and low of Zai Lab Limited - ADR are Rs 44.34 and Rs 15.96 as of 15-May-2026.
What is the market cap of Zai Lab Limited - ADR?
Zai Lab Limited - ADR has a market capitalisation of $ 2,201 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Zai Lab Limited - ADR?
Before investing in Zai Lab Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.